弗吉尼亚大学综合癌症中心的研究团队开发了一种针对胶质母细胞瘤的创新联合疗法,该策略结合了聚焦超声、微小气泡以及携带微RNA的纳米颗粒 1。这项由Roger Abounader教授主导的研究成果于2026年11月1日发布,并刊登在《临床研究杂志》(Journal of Clinical Investigation)上 1。胶质母细胞瘤是一种极具致死性的脑癌,每年在美国造成超过13,000人死亡 1。
该方法的核心机制是利用声波暂时打开血脑屏障,从而将能够同时干扰多个致癌基因的微RNA递送至大脑内部 1。实验数据显示,这种治疗手段在实验室环境和小鼠模型中均成功减缓了肿瘤生长,并延长了实验动物的生存期 1。Abounader指出:“这一新方法可能有助于同时靶向众多促进癌症生长的分子,包括那些目前尚无对应药物的分子,从而实现更好的治疗效果。” 1尽管结果令人鼓舞,但该研究目前仍处于实验阶段,尚未进入临床试验环节 1。
Scientists at the University of Virginia Comprehensive Cancer Center have developed a novel therapeutic strategy that combines focused ultrasound, microbubbles, and nanoparticle-delivered microRNAs to treat glioblastoma, a highly lethal form of brain cancer 1. The research, led by Professor Roger Abounader, was published in the Journal of Clinical Investigation on November 1, 2026, with the DOI 10.1172/JCI195639 1. This approach aims to overcome one of the most significant hurdles in treating central nervous system malignancies: the blood-brain barrier, which typically prevents many drugs from reaching tumor sites effectively 1.
The core mechanism involves using focused ultrasound and microbubbles to temporarily open the blood-brain barrier, allowing nanoparticles carrying microRNAs to penetrate into the brain tissue 1. Once delivered, these microRNAs simultaneously interfere with multiple genes responsible for cancer development 1. In laboratory settings and mouse models, this combined therapy demonstrated reduced tumor growth rates and extended survival times compared to untreated controls 1.
Glioblastoma remains a devastating disease, causing more than 13,000 deaths annually in the United States alone 1. Current treatments often struggle due to the complexity of targeting multiple oncogenic pathways simultaneously 1. "This new approach could help target numerous molecules that promote cancer growth, including those for which no drugs exist, at the same time to achieve better therapies," said Abounader 1. While the results are promising, it is important to note that the treatment is currently experimental and has not yet entered clinical trials 1.
评论
还没有评论,欢迎留下第一条。